home / stock / cydy / cydy news

CYDY News and Press, CytoDyn Inc From 08/14/19

Stock Information
Company Name: CytoDyn Inc
Stock Symbol: CYDY
Market: OTC
Website: cytodyn.com
Menu
CYDY CYDY Quote CYDY Short CYDY News CYDY Articles CYDY Message Board
Get CYDY Alerts

News, Short Squeeze, Breakout and More Instantly...
CYDY - CytoDyn Provides Update on Dose Escalating Trial with Leronlimab for HIV Monotherapy for a Potential Pivotal Trial

564 patients have been enrolled in monotherapy trials to date with over 150 patients hitting the benchmark of one-year of sustained viral suppression The response rate post-10 weeks of monotherapy is 68% with 350 mg dose, 94% with 525 mg and 85% with 700 mg VANCOUVER, Washington, Aug....
CYDY - CytoDyn Files a Phase 2 Protocol with the FDA for Leronlimab (PRO 140) and Regorafenib as a Combination Therapy for Metastatic Colorectal Cancer

VANCOUVER, Washington, Aug. 08, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, an...

CYDY - Patient Treated with Leronlimab (PRO 140) for Metastatic Triple-Negative Breast Cancer under Emergency IND, Launching CytoDyn into Oncology

VANCOUVER, Washington, Aug. 06, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, an...

CYDY - CytoDyn Granted Small Business Waiver of Application Fees by FDA for Leronlimab (PRO 140) BLA Filing

VANCOUVER, Washington, Aug. 05, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, to...
CYDY - CytoDyn Sponsored Research Reaffirms the Role of CCR5 in Cancer Biology and Provides a New Potential Cancer Treatment Modality

VANCOUVER, Washington, Aug. 02, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, to...

CYDY - CytoDyn inks deal to sell PA-14 or PRO 140 for CCR5 for diagnostic use

CytoDyn ( OTCQB:CYDY -11.7% ) executes a license agreement with IncellDX providing the latter with exclusive global rights to sell non-commercial grade quantities of PA-14 (the murine version of PRO 140 for diagnostic use) or PRO 140 for use in the development and commercialization ...

CYDY - CytoDyn Executes Exclusive Worldwide Licensing Agreement with IncellDX for PA-14 and PRO 140 for Diagnostic Testing Purposes

VANCOUVER, Washington, July 26, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, to...
CYDY - CytoDyn Finalizes Development of Receptor Occupancy Test to Guide Pivotal Monotherapy Discussions With the FDA

-       FDA face-to-face meeting granted to discuss pivotal monotherapy trial -       Conference call for investors and media on Tuesday, July 30, 2019 at 4:00 p.m. ET with introduction to Dr. Jonah Sacha for CURE and PrEP progr...

CYDY - The Stock Day Podcast Hosts CytoDyn to Discuss the Addition of Dr. Jonah Sacha to their Team

PHOENIX, AZ / ACCESSWIRE / July 10, 2019 / The Stock Day Podcast welcomed CytoDyn (CYDY) (“the Company”), a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the...

CYDY - New senior science advisor at CytoDyn

CytoDyn ( OTCQB:CYDY ) appoints Dr. Jonah Sacha, Ph.D. as Senior Science Advisor to the Company. More news on: CytoDyn Inc., Healthcare stocks news, Read more ...

Previous 10 Next 10